Spec­trum hits the re­set but­ton, slic­ing away 30% of its work­force in piv­ot around 2 lead as­sets

Covid-19 has been a rough go for many drug­mak­ers, but few more so than Spec­trum Phar­ma­ceu­ti­cals, which has seen in­spec­tion de­lays and un­want­ed CRLs haunt its chance at a first ap­proval. Feel­ing the sting, Spec­trum will now down­size to keep the lights on through the year.

Spec­trum will cut 30% of its work­force and piv­ot its R&D ef­forts around its two fur­thest-along drugs as part of a re­struc­tur­ing ef­fort that will pave the com­pa­ny’s cash run­way out in­to next year, it an­nounced Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER